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THE pROBLEM
Conflicting results of two major randomized trials on prostate cancer mortality (1, 2) have led to 
evolving guidelines for clinicians regarding prostate cancer screening (3–6). While the European 
Randomised Study of Screening for Prostate Cancer (ERSPC) showed that one prostate cancer death 
could be prevented per 781 men screened, the Prostate, Lung, Colorectal, and Ovarian (PLCO) 
Cancer Screening Trial showed no mortality benefit at 13 years of follow-up (1, 2). Because of the 
question of mortality benefit and the possible harms of screening, the United States Preventive 
Services Task Force (USPSTF) initially recommended in 2008 against screening men over age 75 
for prostate cancer (3) then in 2012 against screening for prostate cancer at any age (4). However, it 
is most recently recommended in 2013 by both the American College of Physicians (ACP) and the 
American Urologic Association (AUA) that screening for prostate cancer occurs through a process 
of shared decision making (5, 6). While it is not recommended to screen men for prostate cancer at 
age 70 or above, or men with a life expectancy of less than 10–15 years, for men with average risk of 
developing prostate cancer, these shared decisions should occur between physicians and patients for 
men starting at age 50. For those men with high risk of developing prostate cancer, including men 
with a family history of prostate cancer or African-American men, these conversations could start 
as early as age 40 (5, 6).
Most of these shared discussions will initially occur between men and their primary care physi-
cian. Previous reports of decision aids for prostate cancer screening have shown improvement in 
patient knowledge and in decisional conflict as well as satisfaction with the decision (7). However, 
it is also known that patients may be more likely to be aware of the benefits of screening decisions 
and not the harms, and may ultimately rely on the physician’s recommendation, and it is not clear 
if the use of decision support alters prostate-specific antigen (PSA) testing behavior (8). Indeed, 
the rates of PSA testing were reduced in older men after the initial USPSTF recommendations 
(9–11) and in men over age 50 after the 2012 recommendations (12). However, is it not known 
to what extent shared decision making contributed to the decreased screening rates observed, 
whether shared decision making is occurring more frequently since the ACP and AUA recom-
mendations were released, or to what degree patient or provider factors have contributed to the 
decline in screening rates.
Barriers to shared decision making regarding prostate cancer screening include lack of time for 
discussions as well as physician and patient factors (13–18). Patients may address an average of 25 
problems during some chronic care and primary care visits (19), and cancer screening discussions 
may not be prioritized when management of multiple chronic diseases is also needed during the 
same office visit. More importantly, primary care physicians do not readily have access to tools that 
can promote shared decision making for prostate cancer screening. Elwyn et al. have proposed a 
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model of “choice, option, and decision talk” to be used for shared 
decision making conversations in the clinical encounter (20). For 
a complex decision, such as prostate cancer screening, we propose 
the use of a simple tool in a routine outpatient encounter to begin 
this discussion, to accomplish the first two steps of this model: 
(1) make the patient aware that he has a choice and (2) begin to 
consider the options. We suggest that the decision is discussed 
after the patient has had appropriate time to consider the choice 
and options. This step may occur within the same visit or at a 
later time.
EXpLAnATiOn OF COnSTRUCTS
We propose shared decision making for prostate cancer in a pri-
mary care encounter is based upon nine constructs incorporating 
risk for prostate cancer and patient preferences.
These constructs can provide a framework for the physi-
cian–patient discussion of choice and options regarding prostate 
cancer screening and help the patient to understand the relative 
contribution of each of these constructs to the ultimate choice of 
“Yes, you may benefit from being screened with the PSA” vs. “No, 
you may not benefit from being screened with the PSA.”
Constructs 1–5: Risk for Developing 
prostate Cancer
Age
The risk for developing prostate cancer increases with age. 
The  median age at diagnosis is 66 (21). However, screening 
at age 70 or above is not recommended (5, 6), based upon life 
expectancy (22).
Family History of Prostate Cancer
A family history of prostate cancer increases the relative risk of 
prostate cancer in a man with a first-degree relative with prostate 
cancer to 2.48, with a higher risk in men younger than age 65, or 
if the man’s brother had prostate cancer, and greater risk if more 
than one first-degree relative was affected (23, 24).
High vs. Low Risk Racial/Ethnic Group
African-American men have an increased risk of developing 
prostate cancer compared to Caucasian men, while men from 
Asian and Native American or Alaskan native backgrounds have 
a lower risk. Hispanic ethnicity is also associated with a lower risk 
of developing prostate cancer (21).
History of Previous Digital Rectal Exam
Data from the Prostate Cancer Prevention Trial suggest that the 
odds ratio for having prostate cancer is 2.47 if a man has an abnor-
mal digital rectal exam (DRE) (25) but the sensitivity of the DRE 
is low. It is possible that primary physicians will not routinely 
have performed a DRE for risk stratification.
History of Previous Prostate-Specific Antigen Test
Risk of prostate cancer is predicted by PSA level (25) with recent 
recommendations suggesting different approaches to men using 
PSA cut off levels of <1, 1–3, and >3 ng/ml (26).
Constructs 6–9: patient Self-Reported 
Health Status/preferences
Health Status/Comorbidities
We propose that a patient’s self-reported rating of quality of life 
is incorporated into the decision to offer screening for prostate 
cancer. While this initial tool does not quantitatively address 
comorbidities, we propose that clinicians will make an assessment 
of comorbidities with patients during the screening discussion 
after reviewing the patient’s answer to this question on the tool.
Importance of Urinary Symptoms
Urinary symptoms are a known side effect of prostate cancer 
treatment. Up to 14% of men can experience urinary inconti-
nence 5 years after radical prostatectomy for treatment of prostate 
cancer (27–29). Assessment of the importance of maintaining 
urinary function should be performed as part of the prostate 
cancer screening discussion.
Importance of Maintaining Sexual Function
Erectile dysfunction is also a known side effect of radical 
prostatectomy (27–29) and can affect 50% of men undergoing 
treatment, with slightly lower rates after radiotherapy (30, 31).
Anxiety about Developing Prostate Cancer
Anxiety regarding prostate cancer may be a major driver in the 
screening decision (32, 33), and this issue should be addressed 
prior to making a choice to proceed with screening.
A BRiEF TOOL
While we understand that the decision for prostate cancer screen-
ing is complex, we also appreciate the limited time available to 
discuss this topic in a routine clinical encounter and the proposed 
tool is meant to begin a discussion that incorporates patient 
preferences and is not meant to be comprehensive. We propose 
a tool that can be given to patient within the clinical encounter 
(Table 1). Questions 1–5 address demographic or past medical 
history indicators of prostate cancer risk, while Questions 6–9 
focus on patient preference. While we do not propose a specific 
“cut off ” score to prompt a decision to screen for prostate cancer, 
we have suggested assigned points to answer options based upon 
our available data for each of our constructs.
DiSCUSSiOn
It is extraordinarily difficult to use a tool like this precisely to 
make a screening decision due to the enormous complexity of 
the decision. However, we think this tool could be useful as 
a guide for physicians to identify men who may benefit from 
further discussion vs. those who may not. Extreme values on 
this tool may indicate decisions on whether to screen. Scores 
toward the center values may indicate those who will need 
further thought and discussion, and possibly extensive shared 
decision making. Ideally, a physician would introduce this tool 
during an office visit with a phrase, such as “I would like to 
make you aware of the option you have to choose to have a 
TABLE 1 | proposed screening tool and interpretation based upon constructs.
Question Answer Options with suggested scoring
1. What is your age? ≥70 (0)
65–69 (3)
55–64 (2)
40–54 (1)
<40 (0)
2. What is your race/ethnicity? Select all that apply White/Caucasian (1)
Black/African-American (3)
Asian/Pacific Islander (0)
Native American/Alaskan Native (0)
Hispanic (0)
3. Did any of your family members have prostate cancer? More than one answer 
may apply
My father had prostate cancer (1)
My brother had prostate cancer (2)
More than one family member had prostate cancer (1) please consider only 
those family members related by birth, not by marriage only (skip if both father 
and brother had prostate cancer)
I do not have a family history of prostate cancer or do not know about my family 
history of prostate cancer (0)
4. If you have had a digital rectal exam, what was the result? No previous digital rectal exam (1)
Normal digital rectal exam (0)
Abnormal digital rectal exam (3)
5. If you have had previous prostate-specific antigen (PSA) level what  
was the result?
No previous PSA (1)
PSA < 1.0 (0)
PSA 1.0–3.0 (2)
PSA > 3.0 (3)
6. How would you rate your health? My health is excellent (3)
My health is very good (2)
My health is good (1)
My health is poor (0)
7. If you were to have problems with incontinence (leakage) of urine, how 
bothersome would this be for you?
Not bothersome (3)
Somewhat bothersome (2)
Very bothersome (1)
Extremely bothersome (0)
8. How important is your sex life and maintaining ability to have an erection? Not important (3)
Somewhat important (2)
Very important (1)
Extremely important (0)
9. Are you concerned about having or developing prostate cancer? No, I am not concerned about having or developing prostate cancer (0)
I am a little concerned I may have or may develop prostate cancer (1)
I am very concerned I may have or may develop prostate cancer (2)
I am extremely concerned I may have or may develop prostate cancer (3)
Yes, you may benefit from being screened with the pSA if higher scores: no, you may not benefit from being screened with the pSA if lower scores:
Younger age, treating prostate cancer may have more benefits than risks Older age, treating prostate cancer may have more risks than benefits
Extensive family history of prostate cancer No family history of prostate cancer
Higher risk racial group Lower risk racial group
Abnormal digital rectal exam or no previous digital rectal exam Normal previous digital rectal exam
Previous PSA in higher risk range or no Previous PSA Previous PSA in lower risk range 
Excellent health status, life expectancy not reduced related to comorbid conditions Poor health status, life expectancy reduced related to comorbid conditions
Urinary incontinence would not be bothersome Urinary incontinence would be extremely bothersome
Sex life is not important Sex life is extremely important
Extremely concerned about having or developing prostate cancer Not concerned about having or developing prostate cancer
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screening test to look for prostate cancer. Some men may choose 
this test while others may not based upon their preferences. I 
have a few questions you can answer to help think about this 
option. I can then provide more information for you and we 
can discuss this at your next visit.” An alternative would be to 
have a patient fill out the tool prior to an office visit with a 
plan to discuss the results at the time of the visit. Testing of 
this tool in busy primary care clinical settings is underway, and 
the tool will be refined with continued feedback from clinicians 
and patients.
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